CH273600A - Process for the preparation of a compound of the cyclopentanopolyhydrophenanthrene series which contains an oxygen-containing group in ring C. - Google Patents

Process for the preparation of a compound of the cyclopentanopolyhydrophenanthrene series which contains an oxygen-containing group in ring C.

Info

Publication number
CH273600A
CH273600A CH273600DA CH273600A CH 273600 A CH273600 A CH 273600A CH 273600D A CH273600D A CH 273600DA CH 273600 A CH273600 A CH 273600A
Authority
CH
Switzerland
Prior art keywords
compound
oxygen
ring
preparation
containing group
Prior art date
Application number
Other languages
German (de)
Inventor
Nv Organon
Original Assignee
Nv Organon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nv Organon filed Critical Nv Organon
Publication of CH273600A publication Critical patent/CH273600A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J9/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J3/00Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J5/00Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J7/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J75/00Processes for the preparation of steroids in general

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

  

  Verfahren zur Herstellung einer im Ring C eine sauerstoffhaltige Gruppe  enthaltenden Verbindung der     Cyclopentanopolyhydrophenanthren-Reihe.       Es     wurde    gefunden,     dass    man zu einer im.  Ring C eine sauerstoffhaltige Gruppe enthal  tenden     Verbindung    der     Cyclopentanopoly-          hydrophenanthren-Reihe    gelangen kann, wenn  man     -111,12-Pregnen-3,20-dion    mit     unterhalo-          geniger    Säure behandelt,

   auf das entstandene       Halogenhydrin    unter Bildung eines     Ketohalo-          genids        oxydierende    Mittel einwirken lässt und  hierauf mit reduzierenden Mitteln aus letz  terem das Halogen entfernt.  



  Den Ausgangsstoff kann man unter     an-          derein    aus einem     Acy    l     at    von     Pregnan-12-ol-          3,20-dion        dureb.        thermisehe    Spaltung gewin  nen.  



  Die     unterhalogenige    Säure kann auch z. B.  bei Gegenwart der     Steroidverbindung    aus  ihren Salzen,     lthern    oder Estern oder solchen       Stoffen    erzeugt werden, die in Gegenwart von  Wasser     nnterhalogenige    Säure abgeben, wie  beispielsweise     Bromaeetamid    oder Chloramin.  



  Auf das erhaltene     Halogenhydrin    werden  zuerst     oxydierende    Mittel, z. B. Chromsäure in  Eisessig, dann,     zweeks    Entfernung des Ha  logenatoms, reduzierende Mittel, z. B. Zink  und Eisessig, einwirken gelassen.  



  Das     heue    Verfahrensprodukt., das     Pregnan-          3,17,20-trion    kristallisiert in zu     Drusen    ver  einigten Nadeln vom     Sellmp.    154 bis 156  G.  Es soll als Zwischenprodukt für die     Herstel-          hing    therapeutisch wertvoller Verbindungen  Verwendung finden.         Beispiel:     a) 650 mg     d        ll>12-Pregnen-3,20-dion    vom       Schmp.    131 bis 133  C (erhältlich z.

   B. aus       Pregnan-12-ol-3,20-dion    vorn     Schmp.    182 bis       184     C durch     Benzoylierung        lind    anschliessende  Abspaltung von     Benzoesäure)    werden in  100     ein'    Aceton gelöst, mit 0,6g     N-Brom-          acetamid    und 40 cm' Wasser versetzt und  15 Stunden bei 20  C stehengelassen. Die  anfangs farblose Lösung färbt sich nach  einigen Stunden gelb, ist aber nach 15 Stun  den wieder farblos. lach Zusatz von etwas  Wasser wird das Aceton im Vakuum entfernt,  wobei sieh die Hauptmenge des organischen  Materials als harzige Masse an der Kolben  wand ansetzt.

   Das Wasser wird abgegossen  und das Harz noch zweimal mit wenig     fri-          sehem        -Wasser    gewaschen. Die abgegossenen  Waschwässer werden zweimal mit viel Äther  ausgeschüttelt und das Harz für sieh mit  wenig     abs.    Äther versetzt, wobei reichliche  Mengen von Kristallen ungelöst bleiben, die       abgenutscht,    gut mit. Äther gewaschen und  im     Vakuum    getrocknet werden. Es sind meist  dreieckige, farblose Plättchen, die bei etwa  238 bis     245     C unter Zersetzung schmelzen.

    Sie stellen das     Halogenhydrin    der Formel  
EMI0001.0059     
      b) 420 mg dieses kristallisierten     Halogen-          hydrins    werden in 25     ein'    möglichst alkohol  freiem Chloroform aufgeschwemmt, mit 10 cm'       reinstem    Eisessig und hierauf mit 5     cm3     2      /d        iger        Chromtrioxyd-Eisessig-Lösung    ( =100  Milligramm     Cr0g)    versetzt und 2 Stunden bei  Zimmertemperatur stehengelassen.

   Hierauf  wird das Chloroform im     Vakuum    (bei 20  C       Badtemperatur)    möglichst entfernt, der     Rück-          stand        mit        10        cm"        Eisessig        und        2,5        cm'    2     %        iger          Chromsäurelösung    versetzt und wieder bei  20  C stehengelassen.

   Da nach 3 Stunden  keine freie Chromsäure mehr nachweisbar ist,       werden        erneut        2,5        cm'    2     %        ige        Lösung        zugege-          ben    und dies so oft wiederholt, bis sich nach  dreistündigem Stehen noch deutlich Chromsäure  nachweisen lässt. Insgesamt sind 21 cm' der       2o/oigen    Lösung (= 420 mg     Cr0,)    nötig.

   Die  übliche Aufarbeitung ergibt das     12-Brom-          pregnan-3,11,20-trion    in farblosen Plättchen  vom     Schmp.    176 bis 184 C.  



  c) 240 mg dieses     Ketobromids    werden in  10 cm' Eisessig gelöst, mit 400 mg Zinkstaub  versetzt und unter dauerndem Umschwenken  15 Minuten auf 80  C erwärmt. Durch Fil  trieren, Einengen des Filtrates im Vakuum,  Versetzen mit Nasser und     Ausäthern        erhält.       man das     Pregnan-3,11,20-trion    als in     Drusen     vereinigte Nadeln vom     Sehmp.    154 bis     1,56'C.     



  An Stelle von     N-Bromacetamid        lä.sst    sich  beispielsweise auch Chloramin     verwenden.  



  Process for the preparation of a compound of the cyclopentanopolyhydrophenanthrene series which contains an oxygen-containing group in ring C. It was found that one can become an im. Ring C a compound of the cyclopentanopoly- hydrophenanthrene series containing an oxygen-containing group can be obtained if -111,12-pregnene-3,20-dione is treated with hyphal acid

   allows oxidizing agents to act on the halohydrin formed to form a ketohalide and then removes the halogen from the latter with reducing agents.



  The starting material can be obtained from an acylate of Pregnan-12-ol-3,20-dione, among other things. gain thermal cleavage.



  The hypohalous acid can also be e.g. B. in the presence of the steroid compound from their salts, ethers or esters or those substances which give off interhalogenous acids in the presence of water, such as bromoetamide or chloramine.



  On the halohydrin obtained, oxidizing agents, e.g. B. chromic acid in glacial acetic acid, then, two-way removal of the halogen atom, reducing agents, e.g. B. zinc and glacial acetic acid, allowed to act.



  The current product of the process. Pregnan-3,17,20-trione crystallizes in needles from Sellmp that are united to form drusen. 154 to 156 G. It is said to be used as an intermediate for the production of therapeutically valuable compounds. Example: a) 650 mg d ll> 12-pregnen-3,20-dione with a melting point of 131 to 133 C (available e.g.

   B. from Pregnan-12-ol-3,20-dione from melting point 182 to 184 C by benzoylation and subsequent splitting off of benzoic acid) are dissolved in 100% of an 'acetone, with 0.6 g of N-bromoacetamide and 40 cm' Water was added and the mixture was left to stand at 20 ° C. for 15 hours. The initially colorless solution turns yellow after a few hours, but is colorless again after 15 hours. After adding a little water, the acetone is removed in vacuo, and most of the organic material attaches to the wall of the flask as a resinous mass.

   The water is poured off and the resin is washed twice with a little fresh water. The drained washing water is shaken out twice with a lot of ether and the resin with little abs. Ether added, with copious amounts of crystals remaining undissolved, which sucked off, well with. Ether washed and dried in vacuo. They are mostly triangular, colorless platelets that melt at around 238 to 245 C with decomposition.

    They represent the halohydrin of the formula
EMI0001.0059
      b) 420 mg of this crystallized halohydrin are suspended in chloroform, which is as free of alcohol as possible, with 10 cm of the purest glacial acetic acid and then with 5 cm3 of 2 / d chromium trioxide-glacial acetic acid solution (= 100 milligrams of Cr0g) and 2 hours left to stand at room temperature.

   The chloroform is then removed in vacuo (at a bath temperature of 20 ° C.), the residue is mixed with 10 cm "of glacial acetic acid and 2.5 cm of 2% chromic acid solution and left to stand at 20 ° C. again.

   Since free chromic acid can no longer be detected after 3 hours, another 2.5 cm 2% solution is added and this is repeated until chromic acid can still be clearly detected after standing for three hours. A total of 21 cm 'of the 20% solution (= 420 mg Cr0,) is necessary.

   The usual work-up gives the 12-bromopregnane-3,11,20-trione in colorless platelets with a melting point of 176 to 184 C.



  c) 240 mg of this ketobromide are dissolved in 10 cm 'of glacial acetic acid, 400 mg of zinc dust are added and the mixture is heated to 80 ° C. for 15 minutes with constant swirling. Trier by filtering, concentrating the filtrate in vacuo, adding water and extracting ether. the Pregnan-3,11,20-trione as needles united in drusen from the Sehmp. 154 to 1.56'C.



  Instead of N-bromoacetamide, for example, chloramine can also be used.

 

Claims (1)

PATENTANSPRUCH: Verfahren zur Herstellung einer im Ring C eine sauerstoffhaltige CTruppe enthaltenden Verbindung der Cy elopentanopolhy dropllen- a.nthren-Reihe, dadurch gekennzeichnet, da() man All,lz-Pregnen-3,20-dion mit unterhalo- geniger Säure behandelt, PATENT CLAIM: A process for the preparation of a compound of the Cy elopentanopolhy dropllen- a.nthren series containing an oxygen-containing C troop in ring C, characterized in that () All, lz-pregnene-3,20-dione is treated with hypohalous acid, auf das entstandene Halogenhy drin unter Bildung eines Keto- halogenids oxydierende Mittel einwirken lässt und hierauf mit reduzierenden Mitteln aus letzterem das Halogen entfernt. Das neue Verfahrensprodukt, das Pregnan- 3,11,20-trion kristallisiert. in zu Drusen ver einigten Nadeln vom Sehmp. 1.54 bis 156" C. Es soll als Zwischenprodukt für die Herstel lung therapeutisch wertvoller Verbindungen Verwendung finden. on the resulting halohydin, oxidizing agents can act to form a keto halide, and the halogen is then removed from the latter with reducing agents. The new process product that crystallizes pregnan-3,11,20-trione. in needles of the Sehmp which are united to form drusen. 1.54 to 156 "C. It is intended to be used as an intermediate for the production of therapeutically valuable compounds. UNTERANSPRUCH: Verfahren nach Patentanspruch, dadurch gekennzeichnet, dass unterhalogenige Säure verwendet wird, welche in Gegenwart des Ausgangsstoffes hergestellt -lude. SUBCLAIM: Process according to claim, characterized in that hypohalous acid is used which is produced in the presence of the starting material.
CH273600D 1942-04-25 1942-04-25 Process for the preparation of a compound of the cyclopentanopolyhydrophenanthrene series which contains an oxygen-containing group in ring C. CH273600A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH273600T 1942-04-25
CH251117T 1942-10-08

Publications (1)

Publication Number Publication Date
CH273600A true CH273600A (en) 1951-02-15

Family

ID=25729504

Family Applications (1)

Application Number Title Priority Date Filing Date
CH273600D CH273600A (en) 1942-04-25 1942-04-25 Process for the preparation of a compound of the cyclopentanopolyhydrophenanthrene series which contains an oxygen-containing group in ring C.

Country Status (1)

Country Link
CH (1) CH273600A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2782211A (en) * 1953-09-04 1957-02-19 Ciba Pharm Prod Inc Manufacture of dehydro compounds of the pregnane series

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2782211A (en) * 1953-09-04 1957-02-19 Ciba Pharm Prod Inc Manufacture of dehydro compounds of the pregnane series

Similar Documents

Publication Publication Date Title
DE2051269B2 (en) Process for the preparation of 3-propiony / salicylic acid
CH273600A (en) Process for the preparation of a compound of the cyclopentanopolyhydrophenanthrene series which contains an oxygen-containing group in ring C.
CH417630A (en) Process for the preparation of new cyclic 2,3-O-acetals and 2,3-O-ketals of butanetetrol esters
DE1229526B (en) Process for the preparation of delta 4,1-3-oxo-11beta-hydroxy-19-nor-steroids by introducing oxygen in the 11-position by chemical means
AT217647B (en) Process for the production of the new 16α-methylpregnan - 3α - ol - 11,20 - dione or its esters
AT220298B (en) Process for the production of new 6β-methyl-3-oxo-Δ <4> -steroids
AT346838B (en) PROCESS FOR MANUFACTURING NEW OPTICALLY ACTIVE ANTHRACYCLINONES
DE926552C (en) Process for the production of 19-norprogesterone (A4-19-norpregnen-3, 20-dione)
DE1618053C (en) Process for making steroid compounds
AT160854B (en) Method for the representation of saturated and unsaturated descendants of the Pregnandion (3.20).
AT214922B (en) Process for the preparation of new 1,2,6-substituted piperidones (4) or their salts
AT209007B (en) Process for the preparation of 9 α-halo-4-pregnen-16 α, 17 α, 21-triol-3, 11, 20-triones and their esters
AT274248B (en) Process for the preparation of new derivatives of bufadienolide glycosides
CH275686A (en) Process for the preparation of a compound of the cyclopentanopolyhydrophenanthrene series which contains an oxygen-containing group in ring C.
AT233184B (en) Process for the preparation of 3-oxo-Δ <1,4> steroids
AT265542B (en) Process for the production of new 9β, 10α-steroids
DE1021848B (en) Process for the preparation of therapeutically valuable 4-oxo-2- (haloalkyl) -2,3-dihydro- [benzo-1, 3-oxazines]
DE1040544B (en) Process for the production of 6ª ‡ -Methyl-3-oxo -? - steroids of the androstane and pregnane series
DE1041043B (en) Process for the preparation of 17ª ‡ -hydroxy-16-halogenallopregnanen
CH273596A (en) Process for the preparation of a compound of the cyclopentanopolyhydrophenanthrene series which contains an oxygen-containing group in ring C.
DE1030830B (en) Process for the preparation of 6-hydroxy-3: 5-cyclopregnan-20-one
CH273597A (en) Process for the preparation of a compound of the cyclopentanopolyhydrophenanthrene series which contains an oxygen-containing group in ring C.
CH342210A (en) Method for producing a local anesthetic
DE1101415B (en) Process for the preparation of 6ª ‡ -Methyl-17ª ‡ -acetoxy-4-pregnen-3, 20-dione
CH273598A (en) Process for the preparation of a compound of the cyclopentanopolyhydrophenanthrene series which contains an oxygen-containing group in ring C.